XBI - SPDR S&P Biotech - Stock Price & Dividends
Exchange: USA Stocks • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A8707 • Health
Biotech, Pharmaceuticals, Diagnostics, Research, Therapies
The SPDR S&P Biotech ETF (NYSE ARCA:XBI) is an exchange-traded fund (ETF) designed to track the performance of the S&P Biotechnology Select Industry Index. To achieve this, the fund uses a sampling strategy, investing at least 80% of its total assets in the securities that make up the index.
The S&P Biotechnology Select Industry Index is a subset of the S&P Total Market Index (S&P TMI), which represents the biotechnology sector. This means the ETF provides exposure to a diverse range of biotech companies, from small-cap to large-cap, that are listed on major US stock exchanges.
By investing in the SPDR S&P Biotech ETF, investors can gain access to a broad portfolio of biotech companies, which can help spread risk and potentially increase returns. The fund's diversified holdings can also provide a hedge against market volatility, as the biotech sector is often driven by unique factors such as scientific breakthroughs, regulatory approvals, and industry trends.
As a US-domiciled fund, the SPDR S&P Biotech ETF is subject to US regulatory oversight and is listed on the NYSE ARCA exchange, providing investors with a liquid and transparent trading environment. For more information, investors can visit the fund's website at http://www.spdrs.com.
Drawdown (Underwater) Chart
XBI ETF Overview
Market Cap in USD | 7,116m |
Category | Health |
TER | 0.35% |
IPO / Inception | 2006-01-31 |
XBI ETF Ratings
Growth 5y | 5.76 |
Fundamental | - |
Dividend | 0.00 |
Rel. Performance vs Sector | 0.62 |
Analysts | - |
Fair Price Momentum | 107.81 USD |
Fair Price DCF | - |
XBI Dividends
Dividend Yield 12m | 0.15% |
Yield on Cost 5y | 0.18% |
Dividends CAGR 5y | -50.81% |
Payout Consistency | 40.0% |
XBI Growth Ratios
Growth 12m | 50.17% |
Growth Correlation 12m | 77.9% |
Growth Correlation 3m | 1.6% |
CAGR 5y | 4.21% |
CAGR/Mean DD 5y | 0.12 |
Sharpe Ratio 12m | 1.64 |
Alpha vs SP500 12m | 5.73 |
Beta vs SP500 5y weekly | 1.10 |
ValueRay RSI | 44.63 |
Volatility GJR Garch 1y | 18.57% |
Price / SMA 50 | -0.87% |
Price / SMA 200 | 4.5% |
Current Volume | 6805k |
Average Volume 20d | 6891.5k |
External Links for XBI ETF
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 22, 2024, the stock is trading at USD 98.15 with a total of 6,804,989 shares traded.
Over the past week, the price has changed by -0.93%, over one month by -3.39%, over three months by -0.73% and over the past year by +46.52%.
According to ValueRays Forecast Model, XBI SPDR S&P Biotech will be worth about 120 in October 2025. The stock is currently trading at 98.15. This means that the stock has a potential upside of +22.3%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 120 | 22.3 |